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Introduction: To evaluate the activity of a nonplatinum-, noneto-
poside-containing regimen for patients with extensive stage small
cell lung cancer.
Methods: Patients with untreated extensive stage small cell lung
cancer were treated with gemcitabine 1000 mg/m2 and irinotecan
100 mg/m2 on days 1 and 8 of a 21-day cycle for a maximum of six
cycles. Patients with brain metastases were eligible if asymptomatic
or controlled after radiation.
Results: Eighty-four eligible patients with untreated extensive stage
small cell lung cancer with adequate organ function and a perfor-
mance status of 0–2 were accrued. The median age was 64 years
(range, 42–85) and 45 (54%) were women. Six cycles were com-
pleted by 28 (33%) patients. Some degree of diarrhea occurred in
57% (grade 3/4, 18%). Other grade 3/4 toxicities were neutropenia
(26%), anemia (10%), thrombocytopenia (8%), febrile neutropenia
(5%), fatigue (11%), nausea (10%), and vomiting (8%). The re-
sponse rate was 32% (95% confidence interval: 22%–43%) among
the 81 patients with measurable disease. The median survival was
8.5 months (95% confidence interval: 7.0–9.8) with 1- and 2-year
survival rates of 26% and 7%, respectively. Salvage therapy data
were captured by prospective collection, and only 50% of patients
were treated secondarily.
Conclusion: The overall response rate with the combination of
gemcitabine and irinotecan was disappointing, and the median
survival rate was lower than expected. Further development of this
combination in small cell lung cancer is not recommended.
(J Thorac Oncol. 2007;2: 526–530)
Lung cancer is the leading cause of cancer mortality in theUnited States with an estimated 174,470 deaths in 2006.1
Approximately 15% of these deaths will be caused by small
cell lung cancer, an initially chemotherapy-sensitive but ag-
gressive cancer.2 Cisplatin and etoposide constitute the cur-
rent systemic standard of care for small cell lung cancer in the
United States.3 With concurrent chemoradiotherapy, 15% to
20% of the 30% of patients who present with limited stage
small cell lung cancer may be cured.4 Despite initial response
rates approaching 90%, relapsing patients and those with ex-
tensive stage small cell lung cancer invariably become refractory
to therapy and, ultimately, die of the disease.5 One strategy to
suppress or prevent the emergence of a resistant clone is to use
multiple, non–cross-resistant agents, applied concurrently or
sequentially.6,7 Therapy with concurrent agents is constrained by
overlapping toxicities, and sequential treatment is limited by
inadequate non–cross-resistance.3,8–10 Further progress will re-
quire the development and integration of new agents with
nonoverlapping toxicity or improved cytotoxicity.
Gemcitabine and irinotecan appear to fit this profile in
several respects. Each is independently active in small cell
lung cancer, and the combination can be administered without
reduction in dose intensity. As single-agent therapies, gemcitab-
ine or irinotecan has response rates of 27% to 50%11,12 and 14%
to 47%13–15 for chemotherapy-naive patients and those previ-
ously treated with chemotherapy, respectively. The activity of
irinotecan in extensive stage small cell lung cancer is further
highlighted by findings from JCOG 9511, a phase III study, that
showed irinotecan plus cisplatin to yield superior survival rates
compared with etoposide plus cisplatin.16
As combination therapy, gemcitabine 1000 mg/m2 and
irinotecan 100 mg/m2 administered on days 1 and 8 of a
21-day schedule are well tolerated,17,18 and the combination
demonstrates synergy in vitro over a wide range of doses in
breast and small cell lung cancer cell lines.19 For these
reasons, we chose to evaluate gemcitabine and irinotecan in a
phase II trial to determine the activity and tolerance of this
noncisplatin-, nonetoposide-based combination for patients
with untreated extensive stage small cell lung cancer.
PATIENTS AND METHODS
All patients were required to have (1) histologically
documented small cell lung cancer; (2) extensive stage dis-
ease defined as tumor extending beyond one hemithorax,
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mediastinal, hilar, or supraclavicular area and that could not
be encompassed within a single radiation port (malignant
pleural effusion constituted extensive stage disease); (3) mea-
surable or nonmeasurable disease; (4) no previous chemo-
therapy for this cancer; (5) Zubrod performance score of 0–2;
(6) granulocyte count greater than 1500/l; (7) platelet count
greater than 100,000/l; (8) aspartate aminotransferase and
alanine aminotransferase less than 2.5 times institutional
normal value; and (9) total bilirubin less than 1.25 times
institutional normal value. Required radiographic evaluation
before study participation included computed tomography of
the chest and abdomen and computed tomography/magnetic
resonance imaging of the brain. Brain metastases were al-
lowed if asymptomatic or previously treated with radiation
and no longer associated with symptoms and not requiring
steroid therapy. Ineligibility criteria included pregnancy or
nursing, other active malignancy, or less than a 2-week
duration since surgery. The study was reviewed and approved
by the institutional review board at each participating insti-
tution. Each patient gave informed consent.
Treatment Plan
Gemcitabine 1000 mg/m2 and irinotecan 100 mg/m2
were administered intravenously on days 1 and 8 of a 21-day
cycle for a maximum of six cycles. A 5-HT3 receptor antag-
onist was recommended before therapy. Response evaluation
was performed every two cycles, and therapy was discontin-
ued for disease progression. After completion of protocol
treatment, follow-up data were requested every 3 months for
subsequent chemotherapy and survival.
Dose Modification
Dose modifications were based on toxicity assessed on
the day of treatment. Day 1 therapy was given at full dose if
granulocytes were more than 1500/l and platelets were more
than 100,000/l. Doses were administered at 75% of planned
if granulocytes were less than 1,500/l or platelets were less
than 100,000/l and were delayed 1 week for repeat evalu-
ation if granulocytes were less than 1,000/l or platelets were
less than 75,000/l. If more than a 1-week delay was required
or an episode of febrile neutropenia developed in the patients
during the previous cycle, then all future doses were given at
75% of the original doses. If hematologic recovery had not
occurred within 3 weeks from the planned start date of the
cycle, then the patient was removed from study. For day 8
therapy, both drugs were omitted if granulocytes were less
than 1500/l or platelets were less than 100,000/l.
Dose modifications for nonhematologic toxicity in-
cluded for grade 2/3 diarrhea uncontrolled by loperamide,
withholding irinotecan until the patient improved to grade 1
and then treatment restarted at 75% of dose permanently. For
grade 4 diarrhea uncontrolled by loperamide, irinotecan was
held until toxicity resolved to grade 1 or lower and further
doses were limited to 50% as a permanent dose reduction. For
grade 2 mucositis or higher, both agents were held until
resolution, and permanent dose reductions were implemented
if mucositis reached grade 3/4. If grade 3/4 edema occurred,
the dose of gemcitabine was permanently reduced. For other
nonhematologic drug-related toxicity, excluding nausea, vomit-
ing, fatigue, fever without grade 4 neutropenia, or alopecia,
permanent dose reductions were instituted if grade 2 or higher.
Statistical Planning, Outcome Definitions, and
Analysis Methods
The primary endpoint of the study was overall survival.
A meta-analysis of studies focused on extensive stage small
cell lung cancer using etoposide and cisplatin showed a
median survival of 9.5 months.3 Thus, the results of this trial
would be considered promising if the true median survival
from registration were 13.5 months or longer and would be
considered of no further interest if the true median survival
were 9 months or shorter. The planned accrual of 75 patients
allowed for a one-sided 0.05 level test to rule in favor of
accepting either the null median survival of 9 months or the
alternative of 13.5 months with 89% power. This assumed
12-month accrual period was followed by 12 months of
additional survival follow-up.
It was assumed that 80% of enrolled patients would
have measurable disease. Therefore, response would be as-
sessed in approximately 60 patients, which would be suffi-
cient to estimate the response rate (confirmed plus uncon-
firmed, complete and partial) to within 13% (95%
confidence interval [CI]). Rates of specific toxicities could be
estimated to within, at worst, 12% (95% CI). Any toxicity
occurring with at least 5% probability was likely to be seen at
least once (97.9% chance).
Overall survival (OS) was calculated as the time from
registration to SWOG 0119 to death from any cause or last
contact. Progression-free survival (PFS) was calculated as the
time from registration to SWOG 0119 to either progression of
disease or death from any cause or last contact. Response was
defined using RECIST (Response Evaluation Criteria in Solid
Tumors).20 Survival curves were estimated by the product-
limit method21 and compared using the log-rank test.22
RESULTS
Eighty-five patients were accrued to SWOG 0119 be-
tween January 2002 and February 2003. One patient was
ineligible and was not included for analysis in this data set.
The remaining 84 patients form the basis of this report.
The analyses reported reflect the available data through
July 23, 2005.
The characteristics of the eligible patients are summa-
rized in Table 1. The median age was 64 years (range,
42–85). There were 39 males and 45 females. The perfor-
mance status was 0–1 in 84% and 2 in 16%.
Twenty-eight patients (33%) received all six planned
cycles of chemotherapy. The major reason for not completing
therapy was progression of cancer (37 patients, 44%). Other
reasons included death (six patients, 7.0%), which included
three who were adverse events (9, 11%), refusal (1, 1%), and
development of lymphoma (1, 1%). One patient discontinued
for unknown reasons, and another was removed from protocol
treatment after it was discovered that presumed metastatic
lesions were benign and the patient had been incorrectly
staged at baseline. The median number of cycles received
was four. Grouped by performance status of 0, 1, or 2, the
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median number of cycles received was six, three, three, and
the percentages of patients receiving more than two cycles
were 95%, 74%, and 54%, respectively.
The hematologic and selected common toxicities that
occurred during chemotherapy are listed in Table 2. There
were six deaths potentially related to treatment: aneurysm
(one), myocardial infarction (one), thrombosis (one), arrhyth-
mia (one), hypotension (one), and a death within 30 days of
treatment for which treatment could not be ruled out as a
cause. Grade 3/4 hematologic toxicities were neutropenia
(26%), leukopenia (12%), anemia (10%), and thrombocyto-
penia (8%). Febrile neutropenia occurred in 5%. Diarrhea
occurred in 57% (grade 1 [27%], grade 2 [12%], grade 3
[17%]), grade 4 [1%]). The only other grade 3/4 toxicity
occurring in more than 10% of patients was dyspnea (13%),
which likely was related to malignancy or comorbid disease.
Response was evaluated 6 weeks (two cycles) after the
start of treatment, but was adequately assessed in only 70
(83%) patients. Measurable disease was not a requirement for
study entry. Partial responses, confirmed and unconfirmed,
were seen in 26 of 81 patients with measurable disease (32%;
95% CI: 22%–43%) (Table 3). There were no complete
responses. Stable disease was seen in 15 (19%) and progres-
sion in 27 (32%). The median number of cycles delivered for
those achieving a response, stable disease, or progression was
6, 5, and 2, respectively.
Univariate analyses were performed for overall and
progression-free survival for prognostic factors including
albumin, lactate dehydrogenase, pleural effusion, single ver-
sus multiple lesions, weight loss, and performance status.
Only elevated lactate dehydrogenase above institutional up-
per limit of normal (7 versus 13 months, p  0.002) and
multiple versus single metastatic lesions (8 versus 11 months,
p  0.004) were found to be prognostic for overall survival.
Patients with a performance status of 0 or 1 versus 2 survived
a median of 9 versus 4 months, but the difference was not
significant. Only multiple versus single metastatic lesions
were prognostic for progression-free survival (3 versus 5
months, p  0.03).
Second-line chemotherapy administered after comple-
tion of the trial was recorded in posttreatment follow-up
forms and indicated that only 50% received further treatment.
Seventy-five percent of patients surviving long enough to
complete all protocol therapy (six 21-day cycles or a mini-
mum of 126 days) did go on to receive further treatment. In
all cases, etoposide and either cisplatinum or carboplatin
were delivered as the salvage treatment. Of the patients with
progression, stable disease, or response, 85%, 75%, and 64%
received further treatment, respectively.
Survival and progression-free survival are shown in
Figures 1 and 2. The median progression-free survival was
3.4 months (95% CI: 2.4–3.9). The median survival was 8.5
months (95% CI: 7.0–9.8) with 1- and 2-year overall survival
rates of 26% and 7%, respectively.
DISCUSSION
This large phase II study of gemcitabine and irinotecan
for extensive stage small cell lung cancer was designed to
evaluate a nonplatinum-, nonetoposide-containing regimen
for overall survival. The regimen would be considered prom-
ising if the true median survival were more than 13.5 months
TABLE 1. Patient Characteristics




Age, yr, median (range) 64 (42–85)
60, no. (%) 31 (37)
60–69, no. (%) 28 (33)











TABLE 2. Maximum Toxicity: Hematologic and Selected
Nonhematologic (n  84)
Grade
0 1 2 3 4 5
Anemia 25 38 13 7 1 0
Granulocytopenia 41 3 18 17 5 0
Leukopenia 37 18 19 6 4 0
Thrombocytopenia 56 16 5 7 0 0
Abdominal pain/cramps 64 12 4 4 0 0
Anorexia 46 19 12 7 0 0
Diarrhea 36 23 10 14 1 0
Dyspnea 52 0 20 10 1 0
Fatigue 16 33 26 7 2 0
Febrile neutropenia 80 0 0 3 1 0
Hyponatremia 64 13 0 4 3 0
TABLE 3. Response Evaluation in Patients with Measurable
Disease
Gemcitabine/CPT-11, No. (%)
Complete response 0 (0)
Partial response 14 (17)
Unconfirmed partial response 12 (15)
Stable/no response 15 (19)
Increasing disease 22 (27)
Early death 2 (2)
Symptomatic deterioration 3 (4)
Assessment inadequate 13 (16)
Total 81 (100)
Akerley et al. Journal of Thoracic Oncology • Volume 2, Number 6, June 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer528
and would be considered of no further interest if the median
survival were less than 9 months. With a median survival of
8.5 months, we do not recommend further development of
this regimen as first-line therapy for extensive stage small cell
lung cancer.
There was a discrepancy between response rate and the
median survival for this nonplatinum-, nonetoposide-based
regimen. Although both were low, the overall survival ap-
proached that achieved in meta-analyses of extensive stage
small cell.20 Conversely, the response rate of 32%, the stable
disease rate of 19%, and the progression-free survival of only
3.4 months were particularly low and suggest that only the
minority of patients benefited from this therapy. Accordingly,
the univariate analysis for response was not correlated with
survival. The cause of this discordance is not clear, but one
possible explanation is much of the therapeutic benefit may
have derived from cross-over or second-line treatment. Ar-
guing against this hypothesis is the relatively low percentage
(50%) of patients who were estimated to have received
alternate treatment.
A window of opportunity trial, like this one, has as its
main advantage the prospect of evaluating the activity of
agents in a chemotherapy-naive state. Its disadvantage is that
an ineffective investigational therapy may delay initiation of
known effective treatment or worse, prevent altogether the
use of any second-line treatment if the performance status of
the patients declines sufficiently during investigational ther-
apy. Although overall survival was within acceptable bound-
aries in this trial, it is worrisome that only an estimated 50%
of patients received second-line platinum/etoposide-based
treatment, suggesting that rapid progression and decline of
performance status precluded treatment. For patients who
lived longer than 126 days, the fraction of patients receiving
second-line treatment was greater, ranging from 65% to 85%
depending on response status. This less-than-complete cross-
over should serve as a warning when designing window-of-
opportunity trials with new agents in the setting of tumors
with rapid growth, if conventional treatment has substantial
activity. Prospective, planned capture of second-line treat-
ment is particularly important for this trial design. A two-
stage design with early stopping rules is also warranted.
In summary, we believe that efforts should continue to
develop a treatment that does not share resistance with platinum
or etoposide. Such a regimen, however, must have substantial
activity if it is to be tested as an initial treatment in extensive
stage small cell lung cancer. Otherwise, patients may be
denied the opportunity to receive standard treatment because
of rapid disease progression or deteriorating clinical status.
Gemcitabine and irinotecan are not sufficiently active to
justify further development of this regimen as first-line ther-
apy for extensive stage small cell lung cancer.
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